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SUMMARY
Systemic markers of inflammation are considered reliable predictors of future coro-
nary events in patients with acute myocardial infarction (AMI). The aim of this study was
to evaluate the prognostic relevance of serial C-reactive protein (CRP) measurements in
patients with ST-elevation AMI (STEMI) on one-year outcome. In 31 patients with
STEMI, serial measurements of CRP were obtained, and for each patient, the following
values were determined: (i) values at admission, up to 12 hours after symptom onset, (ii)
maximal values obtained 24-72 hours after symptom onset (early acute values), and (iii)
late acute values (96-120 hours after symptom onset). The combined endpoint was any
new cardiovascular event, including death.
Early and late acute CRP levels were the only parameters found to be significantly
higher in patients with an adverse outcome than in patients with a good outcome. A sig-
nificantly higher rate of endpoint events was found in patients with elevated early (Hazard
ratio [HR] 5.54, 95%CI 2.05-25.40; P = 0.007) and late acute CRP (HR 9.01, 95% CI
1.66-19.56; P = 0.005). Multiple logistic regression analysis identified only early acute
CRP as an independent predictor of an unfavorable outcome (Odds ratio 8.00, 95%CI
1.15-55.60; P = 0.04), after adjustment for established risk factors.
CRP level measured 24-72 hours after symptom onset is an independent predictor of
one-year outcome in patients with STEMI. Values obtained later in the setting of STEMI
do not add further prognostic information. CRP at admission is not related to long-term
prognosis.  (Int Heart J 2006; 47: 833-842)
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THE acute coronary syndromes (ACS), which comprise unstable angina, myo-
cardial infarction without ST-segment elevation, and myocardial infarction with
ST-segment elevation, are multifactor diseases involving both thrombotic and
inflammatory processes.1-4) Numerous studies have identified elevated levels of
markers of inflammation as risk indicators for future cardiovascular events in
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patients with acute myocardial infarction (AMI). Of these markers, C-reactive
protein (CRP) has been the most widely studied, but other biochemical parame-
ters that have also been proposed for risk stratification include white blood cell
count, fibrinogen, cellular adhesion molecules, cytokines, and components of the
complement system.5,6) 
The data from several studies indicate that CRP is an important risk marker
in patients with ST-segment elevation acute myocardial infarction (STEMI). The
predictive value of CRP has been examined in different settings, including the
short-term risk, long-term risk, and risk after revascularisation procedures.7-13)
Careful timing of sampling relative to the onset of symptoms was not performed
routinely in some of the studies, and a broad range of cutoff values has been
reported, concerning mostly the major endpoint events, which all may have
implications for the interpretation of the results. CRP is synthesized in the liver as
part of the acute phase response stimulated by interleukin-6, and a lag period
before CRP levels begin to rise in the circulation was about 12 hours after the
onset of pain in most of the AMI patients.14) CRP levels on admission, therefore,
represent baseline CRP levels, ie, levels that are not the result of myocardial
necrosis. As these levels are higher in individuals with recognized risk factors for
ACS,15-23) indicating that low-grade inflammation may play an important role in
AMI onset, it might be of interest to investigate separately the possible prognostic
values of inflammatory marker levels at admission, and levels when the acute
phase response is fully developed.
The aim of this study was to establish cutoff points that best stratify STEMI
patients into low and high risk groups for the recurrence of any new vascular
event, including death, for CRP (i) at admission, (ii) during the early (24-72 hours
after symptom onset) and (iii) during the late (96-120 hours after symptom onset)
stage of AMI setting, and to evaluate their independent prognostic relevancies in
terms of one-year outcome.
METHODS
Study population: The study population included 31 patients admitted to the
intensive care unit of General Hospital Bor for suspected AMI. All patients met
the following criteria for AMI diagnosis: prolonged central chest pain, elevated
creatine kinase MB (CK-MB) level and ST elevation on electrocardiogram.24)
None of the patients had any sign of interfering noncardiac diseases, such as
inflammatory disorders, malignancy, infection, recent surgery, or trauma.
Patients admitted up to 12 hours after symptom onset received streptokinase,
unless contraindicated. All patients received antiplatelet therapy (aspirin or clopi-
dogrel), unfractionated heparin, GP IIb/IIIa inhibitors, beta-blockers, and, if indi-
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cated, oral ACE inhibitors. No anti-inflammatory drugs, except aspirin, were
administered.
Equipment, reagents, and procedures: Venous blood samples were obtained at
admission and then every 24 hours for 4-5 days. Cholesterol and CK-MB were
determined immediately after venepuncture by standard methods. Serum samples
for CRP determination were stored at -20 °C and assayed in a single batch at the
end of the study. CRP was measured by N High Sensitivity CRP test performed
on a Behring BNTM II Nephelometer (Dade Behring Marburg GmbH, Germany),
using polystyrene particles coated with mouse monoclonal antibodies to CRP.
The detection limit of the assay was 0.175 mg/L for measurements performed
using a sample dilution of 1:20, and the upper reference limit assigned by the
manufacturer was 2.87 mg/L.
For statistical analysis, CRP values were grouped in the following manner:
(i) values obtained at admission, up to 12 hours after symptom onset, (ii) maximal
values obtained 24-72 hours after symptom onset, when peak CRP is expected
(early acute values), and (iii) late acute values (96-120 hours after symptom
onset), when CRP tends to decrease.
During the in-hospital stay, the following relevant data (traditional risk fac-
tors for occurrence of cardiovascular events) were obtained for each patient: age,
sex, smoking status, previous history of unstable angina, hypertension, and diabe-
tes mellitus. All patients provided informed consent for participation in the study.
One-year outcome events were evaluated by direct contact with the patients
who survived the AMI, and by examining their medical charts. For patients who
died during the study, the date and cause of death were obtained from hospital
records. The primary endpoint was the combination of death of any cause and any
new vascular event (new episode of unstable angina requiring readmission to hos-
pital, surgical revascularisation of myocardium, and new AMI), whichever came
first during the one-year period of follow-up.
Statistics: Continuous variables are described as mean or median values, accord-
ing to the manner of distribution. The degree of univariate association between
dichotomous variables and endpoints was examined by Fisher's exact test. Com-
parisons between the 2 groups for continuous variables were performed with an
unpaired t test and Mann-Whitney test, as appropriate. For continuous variables
shown to be significantly different between the groups, cutoff points were estab-
lished via a receiver operator characteristic (ROC) curve. These cutoffs were
tested in survival analysis and included in multiple regression models. The
Kaplan-Meier technique (log rank test) was applied in survival analysis. The mul-
tivariate association between variables (CRP and traditional risk factors: age, sex,
smoking, hypercholesterolemia, hypertension, unstable angina, diabetes melli-
tus) and unfavorable outcome was evaluated with forward stepwise multiple
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logistic regression analysis. For all tests, a two-tailed P value < 0.05 was consid-
ered statistically significant.
RESULTS
A total of 31 patients (24 men and 7 women, mean age, 59 years, range, 33-
78 years) were enrolled in the study according to the aforementioned criteria for
AMI. Of them, 14 (45%) had a history of hypertension, 7 (23%) had a history of
unstable angina, 4 (13%) had diabetes mellitus, and 15 (48%) reported being cur-
rent smokers.
The median time from the onset of chest pain to admission was 9 (range, 1-
48) hours. For 10 patients, the interval between symptom onset and admission
exceeded 12 hours, and their data on admission were not included in the statistical
analysis.
The time course of CRP levels showed 3 different patterns (Figure 1). In 17
(55%) patients (Figure 1a), typical acute phase response was recorded; CRP rose
from admission, peaked between 24-72 hours after the onset of pain, and then
decreased. In 9 (29%) patients, (Figure 1b) a persistent rise in CRP was observed,
and in 5 (16%) patients, (Figure 1c) CRP levels remained normal or slightly ele-
vated during the entire observation period.
At the end of the observation period (mean, 13.9 months, range, 12-15
months) one-year outcome was determined, and in 15 patients the following end-
point events were recorded: 4 patients died of cardiovascular causes, 1 had a new
AMI, 8 had an episode of unstable angina requiring new admission to hospital,
Figure 1. Patterns of CRP kinetics during the setting of acute myocardial infarction
with ST-elevation: (a) typical acute phase response in 55% of patients, (b) persistently
increasing pattern in 29% of patients, and (c) persistently normal or slightly elevated lev-
els in 16% of patients.
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and 2 patients had undergone percutaneous transluminal coronary angioplasty
(PTCA). Of the remaining 16, 14 were found to be free of cardiovascular events
and 2 were lost to follow-up. During the follow-up period, all patients received
secondary preventive treatment with aspirin or warfarin, statins, and nitrates and
calcium-channel blockers, when necessary.
Comparison data for the patients who were free of cardiovascular events
(good outcome) and those who had a primary endpoint (adverse outcome) during
the follow-up period are presented in Table I. Patients with an adverse outcome
had significantly higher median levels of early and late acute CRP. Levels of CRP
at admission were not significantly different between the groups. In addition,
patients who had a primary endpoint were older than patients who were free of
coronary events. The values of other traditional risk factors were not significantly
different between the groups. Since the early and late acute CRP levels were the
only inflammatory parameters found to be significantly different between the
groups, only these 2 values were further analyzed.
Using ROC curve analysis, the cutoff points were established to be 48.3 mg/
L (sensitivity 75.0%, specificity 85.7%, area under the curve 0.79 ± 0.09) for
early acute CRP and 18.5 mg/L (sensitivity 91.7%, specificity 69.2%, area under
the curve 0.79 ± 0.09) for late acute CRP. These cutoffs were tested in survival
analysis. It was found that the rate of occurrence of cardiovascular events during
the one-year period of follow-up was higher in patients who had early (Hazard
ratio [HR] 5.54, 95%CI 2.05-25.40; P = 0.0071) and late (HR 9.01, 95%CI 1.66-
19.56; P = 0.0045) acute levels of CRP above the established cutoff points (Table
II). Kaplan-Meier survival curves of patients with CRP levels above and below
Table I. Comparison Data of the Patients With Good and Adverse One-year Out-
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the cutoff points are shown in Figure 2A, for early acute values, and in Figure 2B,
for late acute values of CRP. A higher rate of endpoint events was also found in
older (> 60 years) patients (HR 4.23, 95%CI 1.78-17.33; P = 0.031).
Multiple logistic regression analysis was performed to valuate the indepen-
dent contribution of CRP levels to the risk of death or a new vascular event. Two
models were performed, for early and for late acute CRP. It was shown that the
only independent predictor of long-term cardiac outcome was the early acute
CRP level (Odds ratio [OR] 8.00, 95%CI 1.15-55.60; P = 0.036), after adjustment
A
B
Figure 2. Kaplan-Meier curves for risk of death or new vascular events after one
year of follow-up in patients with CRP levels above and below the cutoff levels (A)
24-72 hours after symptom onset, and (B) 96-120 hours after symptom onset.
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for established risk factors. Late acute CRP levels were not independently related
to one-year outcome. Significance was lost when variable age was included in the
model (unadjusted OR 12.57, 95%CI 1.28- 123.49; P = 0.030, and adjusted OR
6.06, 95%CI 0.51-71.62; P = 0.153).
DISCUSSION
A growing body of evidence suggests that markers of inflammation may be
reliable predictors of outcome in patients with ACS. Several studies have indi-
cated that CRP is an important risk marker in patients with ST segment elevation
AMI.7-11) CRP is the most promising prognostic marker for its analytical proper-
ties: CRP has a long half-life, no diurnal variations in concentrations, a rapid
acute phase response, and is easily measured by commercially available standard-
ized assays.
In this study, we investigated the prognostic relevancies of CRP in patients
with STEMI in terms of one-year outcome. We observed that changes in this
inflammatory marker in the setting of AMI had different time-courses. Differ-
ences in the individual acute phase response have been observed in the earliest
studies on CRP kinetics after AMI.25,26) We showed that changes in CRP levels
had 3 distinctive patterns, with possible different prognostic messages (Figure 1):
(a) typical acute phase response, with peak CRP levels between 24-72 hours after
onset of pain, (b) a persistently increasing pattern, and (c) persistently normal val-
ues or slightly elevated pattern of CRP kinetics. Because all patients received
similar medical treatment, it could be speculated that the intensity and pattern of
the individual inflammatory response may be an independent pathogenic compo-
nent of AMI.
Table II. Univariate Predictors of One-year Combined Endpoint Events for
Patients With Acute Myocardial Infarction With ST-elevation
Prognostic variable HR 95% CI P
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In accordance with previous studies,7-10,27,28) we found that AMI patients who
had a primary endpoint during the one year of follow-up, had significantly higher
median levels of early (peak) and late acute CRP, compared with the patients who
were free of cardiovascular events. CRP levels at admission were not signifi-
cantly different between the groups in our study (Table I). Higher CRP values at
admission were found to be predictive of new cardiovascular events in some stud-
ies. However, these studies investigated either the predictive value of high CRP
on short-term outcome,27,29) or when the time interval between the onset of pain
and admission exceeded 12 hours,8,27) or CRP was not measured using an ultra
sensitive assay.30) 
CRP levels measured 24-72 hours after symptom onset remained a signifi-
cant prognostic marker of one-year outcome, after correction for established risk
factors, in our study. These results are in accordance with the results of oth-
ers,7,8,27) concerning the prognostic relevance of peak CRP levels. Peak CRP level
was not an independent prognostic marker in a study that investigated the 3-year
outcome after AMI,28) which, we think, is not necessarily in discordance with our
finding, and may suggest that the predictive value of CRP weakens over time.
However, in the present study, increased CRP levels measured 4-5 days after
symptom onset, although better associated with an unfavorable outcome than
peak CRP levels (Table II, Figure 2), were not independently related to long-term
prognosis when adjusted for age in a multiple regression model. This finding sug-
gests that persistently high or an increasing pattern of the CRP acute phase
response is predominantly associated with older age. Still, the meaning of a con-
tinued elevation of CRP levels after AMI needs to be further elucidated, as an
understanding of the causes of persistent inflammation may provide additional
therapeutic tools.31) 
The cutoff points reported in previous studies differed according to the end-
point events investigated. Berton, et al 27) reported a third day CRP cutoff value of
85 mg/L for one-year total and heart failure mortality, while Anzai, et al 9) found
that a peak CRP level greater then 200 mg/L was an independent predictor of car-
diac rupture and one-year cardiac death. In the present study, the cutoff values
that best discriminated between the patients with good and adverse one-year out-
come (combined endpoint: death and any new vascular event) were 48.3 mg/L for
early acute and 18.5 mg/L for late acute CRP. The broad range of reported cutoffs
in the literature implies that the optimal cutoff for defining high CRP concentra-
tions among patients with AMI remains to be determined.
Although based on a small number of patients, our results confirmed that the
inflammatory process, represented by CRP elevation, has an important role in the
pathogenesis of future coronary events in patients with STEMI. In these patients,
a single measurement of CRP 24-72 hours after symptom onset may be useful as
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an independent marker for assessing the likelihood of recurrent events, including
death, in the following year.
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